FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316077571> ?p ?o ?g. }

• W4316077571 endingPage "e565" @default.
• W4316077571 startingPage "e565" @default.
• W4316077571 abstract "Introduction: MORF-057 is a potent and selective α4β7 integrin inhibitor being developed as an oral treatment for patients with inflammatory bowel disease. In a previously reported Phase 1 study in healthy subjects (NCT04580745) MORF-057 was well tolerated and demonstrated favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties at doses up to 100 mg twice daily (BID). This study evaluated second generation formulation and the multidose assessment to 200 mg BID. Methods: An immediate release formulation in capsules at dosage strengths of 25 and 100 mg was used for this study. This was a two-part healthy volunteer study where Part 1 investigated the safety and PK of a single administration of 25 mg (fasted) and 100 mg (fasted, fed) MORF-057. Part 2 investigated the safety, PK and PD of a single dose of 200 mg MORF-057 followed, after washout, by 14 days of repeat dosing at 200 mg BID. Blood samples to assess PK (Part 1 and 2) and receptor occupancy (RO; Part 2 only) of α4β7 and α4β1 integrins were obtained prior to the first dose and 12 hours post-dose. Changes in lymphocyte subsets (LS) and expression of C-C Motif Chemokine Receptor 9 (CCR9) mRNA in blood were also measured in Part 2 of the study. (Figure) Results: A total of 20 subjects were enrolled in the study (n=8 in Part 1; n=12 in Part 2). Three non-serious adverse events (AEs) were reported. No AEs were deemed related to MORF-057, and no safety signals were identified. Approximately dose proportional exposures of MORF-057 was observed following single administration at doses from 25 to 200 mg. MORF-057 was rapidly absorbed with a Tmax ranging from 2-4 hours. The high fat meal delayed the absorption resulting in a slight decrease in AUC (23%) and Cmax (49%) and an increase in Ctrough (46%). Saturating α4β7 RO (99%) was achieved at 12 hours following a single 200 mg dose and was sustained over multiple doses at 200 mg BID. α4β1 RO was below the limit of quantitation. The B cells and T cell subsets, and expression of CCR9 mRNA in blood, were elevated at Day 19 during BID dosing. (Table) Conclusion: Single and multiple dose MORF-057 was well tolerated in this study. Compared with data from a previous study, biomarker responses are consistent between 100 and 200 mg BID suggesting saturation of biomarker effect. MORF-057 demonstrated a favorable PK and PD profile supporting further clinical development.Figure 1.: α4β7 receptor occupancy (RO) Following Multiple Oral Administration of 200 mg BID MORF-057 Data presented as boxplots with central line representing the median value; α4β7 RO was measured at trough (12 h post dose) after a single administration (Day1_12h) and during repeat dose administration at 200 mg BID (Day6_12h, Day12_12h, Day19_12h). Table 1. - Summary of Plasma MORF-057 PK Parameters Following Single Dose Administration AUC, Cmax, and C12, values are presented as geometric mean (geometric CV%). Tmax is presented as median (min, max) PharmacokineticParameter (Unit) Part 1 Period 1100 mg MORF-057 IRCapsules (Fasted)(N=8) Part 1 Period 2100 mg MORF-057 IRCapsules (Fed)(N=7) Part 1 Period 325 mg MORF-057 IRCapsules (Fasted)(N=7) Part 2200 mg MORF-057 IRCapsules (Fasted)(N=9) AUC0-inf (h*ng/mL) 2050 (51.2) 1660 (41.1) 604 (36.5) 3770 (30.3) Cmax (ng/mL) 545 (45.9) 299 (48.7) 139 (38.6) 970 (46.6) C12 (ng/mL) 19.0 (81.9) 35.1 (98.6) 5.98 (61.8) 40.0 (44.1) Tmax (h) 2.01 (1.02, 4.02) 4.00 (1.50, 4.00) 1.50 (1.00, 2.50) 2.50 (1.52, 4.02) NA = Not Applicable." @default.
• W4316077571 created "2023-01-14" @default.
• W4316077571 creator A5000923779 @default.
• W4316077571 creator A5006645491 @default.
• W4316077571 creator A5011461245 @default.
• W4316077571 creator A5029559868 @default.
• W4316077571 creator A5031221529 @default.
• W4316077571 creator A5031309843 @default.
• W4316077571 creator A5042070304 @default.
• W4316077571 creator A5050750757 @default.
• W4316077571 creator A5069567970 @default.
• W4316077571 creator A5073284312 @default.
• W4316077571 creator A5073522470 @default.
• W4316077571 creator A5075436982 @default.
• W4316077571 creator A5077439570 @default.
• W4316077571 creator A5078998491 @default.
• W4316077571 creator A5085208430 @default.
• W4316077571 creator A5087921031 @default.
• W4316077571 date "2022-10-01" @default.
• W4316077571 modified "2023-09-26" @default.
• W4316077571 title "S793 Full Target Engagement With Saturation of α4β7 Integrin Receptor Occupancy Resulting in Changes in Subset of Lymphocytes by MORF-057 Following 200 Mg Daily Dosing in Healthy Subjects" @default.
• W4316077571 doi "https://doi.org/10.14309/01.ajg.0000859812.26766.04" @default.
• W4316077571 hasPublicationYear "2022" @default.
• W4316077571 type Work @default.
• W4316077571 citedByCount "0" @default.
• W4316077571 crossrefType "journal-article" @default.
• W4316077571 hasAuthorship W4316077571A5000923779 @default.
• W4316077571 hasAuthorship W4316077571A5006645491 @default.
• W4316077571 hasAuthorship W4316077571A5011461245 @default.
• W4316077571 hasAuthorship W4316077571A5029559868 @default.
• W4316077571 hasAuthorship W4316077571A5031221529 @default.
• W4316077571 hasAuthorship W4316077571A5031309843 @default.
• W4316077571 hasAuthorship W4316077571A5042070304 @default.
• W4316077571 hasAuthorship W4316077571A5050750757 @default.
• W4316077571 hasAuthorship W4316077571A5069567970 @default.
• W4316077571 hasAuthorship W4316077571A5073284312 @default.
• W4316077571 hasAuthorship W4316077571A5073522470 @default.
• W4316077571 hasAuthorship W4316077571A5075436982 @default.
• W4316077571 hasAuthorship W4316077571A5077439570 @default.
• W4316077571 hasAuthorship W4316077571A5078998491 @default.
• W4316077571 hasAuthorship W4316077571A5085208430 @default.
• W4316077571 hasAuthorship W4316077571A5087921031 @default.
• W4316077571 hasBestOaLocation W43160775711 @default.
• W4316077571 hasConcept C111113717 @default.
• W4316077571 hasConcept C112705442 @default.
• W4316077571 hasConcept C126322002 @default.
• W4316077571 hasConcept C170493617 @default.
• W4316077571 hasConcept C197934379 @default.
• W4316077571 hasConcept C2777288759 @default.
• W4316077571 hasConcept C2777761686 @default.
• W4316077571 hasConcept C2779591629 @default.
• W4316077571 hasConcept C3017940444 @default.
• W4316077571 hasConcept C71924100 @default.
• W4316077571 hasConcept C90924648 @default.
• W4316077571 hasConcept C98274493 @default.
• W4316077571 hasConceptScore W4316077571C111113717 @default.
• W4316077571 hasConceptScore W4316077571C112705442 @default.
• W4316077571 hasConceptScore W4316077571C126322002 @default.
• W4316077571 hasConceptScore W4316077571C170493617 @default.
• W4316077571 hasConceptScore W4316077571C197934379 @default.
• W4316077571 hasConceptScore W4316077571C2777288759 @default.
• W4316077571 hasConceptScore W4316077571C2777761686 @default.
• W4316077571 hasConceptScore W4316077571C2779591629 @default.
• W4316077571 hasConceptScore W4316077571C3017940444 @default.
• W4316077571 hasConceptScore W4316077571C71924100 @default.
• W4316077571 hasConceptScore W4316077571C90924648 @default.
• W4316077571 hasConceptScore W4316077571C98274493 @default.
• W4316077571 hasIssue "10S" @default.
• W4316077571 hasLocation W43160775711 @default.
• W4316077571 hasLocation W43160775712 @default.
• W4316077571 hasOpenAccess W4316077571 @default.
• W4316077571 hasPrimaryLocation W43160775711 @default.
• W4316077571 hasRelatedWork W1590282786 @default.
• W4316077571 hasRelatedWork W1988935887 @default.
• W4316077571 hasRelatedWork W1990079369 @default.
• W4316077571 hasRelatedWork W2021831895 @default.
• W4316077571 hasRelatedWork W2096040265 @default.
• W4316077571 hasRelatedWork W2152560731 @default.
• W4316077571 hasRelatedWork W2207503964 @default.
• W4316077571 hasRelatedWork W2899072855 @default.
• W4316077571 hasRelatedWork W2922882148 @default.
• W4316077571 hasRelatedWork W2108030623 @default.
• W4316077571 hasVolume "117" @default.
• W4316077571 isParatext "false" @default.
• W4316077571 isRetracted "false" @default.
• W4316077571 workType "article" @default.